Enliven Therapeutics Inc (ELVN)
Featured in
Overvalued Stocks
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule inhibitors for cancer treatment. The company’s pipeline includes ELVN-001, a small-molecule kinase inhibitor being studied in Phase 1 for adults with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to reach the central nervous system, which is also in Phase 1 testing for non-small cell lung cancer and other HER2-mutant tumors. Enliven Therapeutics was founded in 2019 and is based in Boulder, Colorado. Its common stock is listed on the NASDAQ under the symbol ELVN.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ELVN
|
$29.34
|
-45.1% Downside
|
Overvalued
|
$66.89
|
25.1% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-37.8x
|
8.2x
|
—
|
3.608 B
|
3.28 B
|
0.0%
|
87.5%
|
187.7
|
—
|
66.4%
|
